PROTEK Group announces FY-2017 financial results

20.04.2018

PROTEK Group (PRTK: MICEX), one of the major pharmaceutical companies in Russia operating in all the segments of the pharmaceutical market (production, distribution, and retail sales), has announced its audited IFRS results for FY-2017. 

In 2017, the Group’s consolidated IFRS revenue increased by 7% y-o-y to RUB 258,455 mln.

The Group achieved a consolidated gross profit of RUB 31,391 mln., driving the gross margin to 12.1%.

The Group’s consolidated EBITDA amounted to RUB 9,518 mln., with EBITDA margin reaching 3.7%. 

The Group’s and Segments’ Financial Highlights, FY-2017:

 

Revenue,

RUB, m.

Gross Profit,

RUB, m.

Gross          Margin, %

EBITDA

RUB, m.

EBITDA
Margin %

GROUP

258,455

31,391

12.1%

9,518

3.7%

Distribution

218,504

11,239

5.1%

3,904

1.8%

Retail Sales

50,222

13,454

26.8%

2,260

4.5%

Production

11,968

7,040

58.8%

3,941

32.9%

   The Group’s and Segments’ Financial Highlights, FY-2016:

 

Revenue,

RUB, m.

Gross Profit,

RUB, m.

Gross          Margin, %

EBITDA adj.*

RUB, m.

EBITDA Adj Margin %

GROUP

241,482

29,428

12.2%

10,427

4.3%

Distribution

211,099

12,495

5.9%

5,652

2.7%

Retail Sales

40,181

11,338

28.2%

2,033

5.1%

Production

10,656

6,100

57.2%

3,390

31.8%

*EBITDA adjusted in 2016 (adjusted for legal claims)

Mr. Vadim Muzyaev, President of PROTEK Group, has commented on the FY-2017 financial results: “The Group’s consolidated revenue growth rate amounted to 7% y-o-y that is slightly lower than market growth rate (9% according to IQVIA data). The increase in revenue was showed by all Group segments: Distribution Segment (+3.5%), Retail Segment (25.0%) and Production Segment (12.3%)”. 

***

Matters discussed in this document may constitute forecasts and other forward-looking statements concerning future events or financial performance of the Company.  The words “believe”, “expect”, “anticipate”, “intend”, “plan”, “estimate”, “aim”, “forecast”, “project”, “will”, “may”, “might”, “should”, “could” and similar expressions (or their negative) identify certain of these forward-looking statements.

The Company warns that these forward-looking statements are but forecasts that may differ significantly from actual events and performance.  The Company does not intend to supplement, amend, update or revise any of the forward-looking statements contained in this document to reflect any events or circumstances occurring after the publication of this document, or any extraordinary circumstances.

Multiple factors, including, in particular, overall economic conditions, competitive environment and many other risks inherent to the Company and its operations, may result in actual performance differing substantially from these forecasts and forward-looking statements of the Company.

 

News list
сотекс Рафарма протеин протек транссервис
спарго протек-свм ригла протек фонд
Проаптека